UB Paderborn / Katalog / Suche / in CDI

Exploring the spatial variation of mercury in the Gulf of St. Lawrence using northern gannets as fish samplers

The Science of the total environment, 2024-06, Vol.927, p.172152-172152, Article 172152

2024

Volltextzugriff (PDF)

Exposure to Contaminated River Water is Associated with Early Hatching and Dysregulation of Gene Expression in Early Life Stages of the Endangered Copper Redhorse (Moxostoma hubbsi)

Environmental toxicology and chemistry, 2022-08, Vol.41 (8), p.1950-1966

2022

Volltextzugriff (PDF)

An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry

Chest, 2012-08, Vol.142 (2), p.448-456

2012

Volltextzugriff (PDF)

Tadalafil Therapy for Pulmonary Arterial Hypertension

Circulation (New York, N.Y.), 2009-06, Vol.119 (22), p.2894-2903

2009

Volltextzugriff (PDF)

Pediatric Pulmonary Hypertension

Journal of the American College of Cardiology, 2013-12, Vol.62 (25), p.D117-D126

2013

Volltextzugriff (PDF)

Pulmonary Arterial Hypertension: Baseline Characteristics From the REVEAL Registry

Chest, 2010-02, Vol.137 (2), p.376-387

2010

Volltextzugriff (PDF)

Bosentan Therapy for Pulmonary Arterial Hypertension

The New England journal of medicine, 2002-03, Vol.346 (12), p.896-903

2002

Volltextzugriff (PDF)

Survival with first-line bosentan in patients with primary pulmonary hypertension

The European respiratory journal, 2005-02, Vol.25 (2), p.244-249

2005

Volltextzugriff (PDF)

Four- and Seven-Year Outcomes of Patients With Congenital Heart Disease–Associated Pulmonary Arterial Hypertension (from the REVEAL Registry)

The American journal of cardiology, 2014, Vol.113 (1), p.147-155

2014

Volltextzugriff (PDF)

Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society

Circulation (New York, N.Y.), 2015-11, Vol.132 (21), p.2037-2099

2015

Volltextzugriff (PDF)

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

Annals of internal medicine, 2000-03, Vol.132 (6), p.425

2000

Volltextzugriff (PDF)

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

Thorax, 2005-12, Vol.60 (12), p.1025-1030

2005

Volltextzugriff (PDF)

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension

Circulation (New York, N.Y.), 2012-01, Vol.125 (2), p.324-334

2012

Volltextzugriff (PDF)

Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension)

International journal of cardiology, 2016-01, Vol.203, p.325-330

2016

Volltextzugriff (PDF)

Portopulmonary Hypertension: A Report From the US-Based REVEAL Registry

Chest, 2012-04, Vol.141 (4), p.906-915

2012

Volltextzugriff (PDF)

Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)

Circulation (New York, N.Y.), 2010-07, Vol.122 (2), p.164-172

2010

Volltextzugriff (PDF)

Sitaxsentan Therapy for Pulmonary Arterial Hypertension

American journal of respiratory and critical care medicine, 2004-02, Vol.169 (4), p.441-447

2004

Volltextzugriff (PDF)

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association

Journal of the American College of Cardiology, 2009-04, Vol.53 (17), p.1573-1619

2009

Volltextzugriff (PDF)

Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2008-01, Vol.51 (2), p.161-169

2008

Volltextzugriff (PDF)

Validation of two predictive models for survival in pulmonary arterial hypertension

The European respiratory journal, 2015-07, Vol.46 (1), p.152-164

2015

Volltextzugriff (PDF)

Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects

Circulation (New York, N.Y.), 1999-04, Vol.99 (14), p.1858-1865

1999

Volltextzugriff (PDF)

Beraprost therapy for pulmonary arterial hypertension

Journal of the American College of Cardiology, 2003-06, Vol.41 (12), p.2119-2125

2003

Volltextzugriff (PDF)

The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States: How REVEAL Differs From Historic and Non-US Contemporary Registries

Chest, 2011, Vol.139 (1), p.128-137

2011

Volltextzugriff (PDF)

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines

Chest, 2004-07, Vol.126 (1 Suppl), p.35S-62S

2004

Volltextzugriff (PDF)

Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice

The European respiratory journal, 2013-09, Vol.42 (3), p.689-700

2013

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Exploring the spatial variation of mercury in the Gulf of St. Lawrence using northern gannets as fish samplers

Exposure to Contaminated River Water is Associated with Early Hatching and Dysregulation of Gene Expression in Early Life Stages of the Endangered Copper Redhorse (Moxostoma hubbsi)

An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry

Tadalafil Therapy for Pulmonary Arterial Hypertension

Pediatric Pulmonary Hypertension

Pulmonary Arterial Hypertension: Baseline Characteristics From the REVEAL Registry

Bosentan Therapy for Pulmonary Arterial Hypertension

Survival with first-line bosentan in patients with primary pulmonary hypertension

Four- and Seven-Year Outcomes of Patients With Congenital Heart Disease–Associated Pulmonary Arterial Hypertension (from the REVEAL Registry)

Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension

Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension)

Portopulmonary Hypertension: A Report From the US-Based REVEAL Registry

Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)

Sitaxsentan Therapy for Pulmonary Arterial Hypertension

Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension

Validation of two predictive models for survival in pulmonary arterial hypertension

Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects

Beraprost therapy for pulmonary arterial hypertension

The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States: How REVEAL Differs From Historic and Non-US Contemporary Registries

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines

Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice

Suchergebnisse filtern